1. Home
  2. AER vs ALNY Comparison

AER vs ALNY Comparison

Compare AER & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AerCap Holdings N.V.

AER

AerCap Holdings N.V.

SELL

Current Price

$167.18

Market Cap

23.6B

ML Signal

SELL

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$150.26

Market Cap

21.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AER
ALNY
Founded
1995
2002
Country
Ireland
United States
Employees
N/A
115
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.6B
21.6B
IPO Year
2006
2004

Fundamental Metrics

Financial Performance
Metric
AER
ALNY
Price
$167.18
$150.26
Analyst Decision
Strong Buy
Buy
Analyst Count
10
30
Target Price
$186.60
★ $284.96
AVG Volume (30 Days)
1.1M
★ 3.1M
Earning Date
10-28-2026
10-29-2026
Dividend Yield
★ 0.95%
N/A
EPS Growth
N/A
★ 206.88
EPS
N/A
★ 18.42
Revenue
N/A
★ $1,037,418,000.00
Revenue This Year
$6.11
$46.31
Revenue Next Year
N/A
$17.44
P/E Ratio
★ $7.27
$8.02
Revenue Growth
N/A
★ 22.88
52 Week Low
$130.12
$146.51
52 Week High
$183.22
$479.79

Technical Indicators

Market Signals
Indicator
AER
ALNY
Relative Strength Index (RSI) 60.94 27.15
Support Level $133.19 N/A
Resistance Level N/A $235.28
Average True Range (ATR) 4.11 7.83
MACD -0.34 0.38
Stochastic Oscillator 36.43 5.30

Price Performance

Historical Comparison
AER
ALNY

About AER AerCap Holdings N.V.

AerCap Holdings NV is an aircraft leasing company. Its activities include leasing, financing, sales, and management of commercial aircraft and engines. It also provides aircraft asset management and corporate services to securitization vehicles, joint ventures, and other third parties. It has one business segment: leasing, financing, sales, and management of commercial flight equipment (Commercial Flight Equipment Segment). Through its subsidiary, the group also provides engine leasing, certified aircraft engines, airframes, and engine parts. Its geographical segments include China, the United States, and Other countries.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Share on Social Networks: